Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain.
Neuropathic pain sometimes needs invasive pain therapy. We present the case of a patient with cancer-related neuropathic pain untreatable with conventional pain therapy after tumour-embolization. The patient was treated successfully with intrathecal (i.t.) administration of S(+)-ketamine, in addition to morphine. Plasma concentrations of S(+)-ketamine were measured regularly throughout the treatment. Continuous i.t. administration of S(+)-ketamine over a period of 3 months demonstrated low plasma levels and no unwanted side-effects.
Benrath
J
J
Department of Anaesthesiology and Intensive Care B, Medical University Vienna, Vienna, Austria. justus.benrath@meduniwien.ac.at
Scharbert
G
G
Gustorff
B
B
Adams
H-A
HA
Kress
H G
HG
D000700:Analgesics; D003000:Clonidine; D004361:Drug Tolerance; D006801:Humans; D007278:Injections, Spinal; D007649:Ketamine; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D009020:Morphine; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D010166:Palliative Care / Q000379:methods*; D013125:Spinal Neoplasms / Q000150:complications / Q000188:drug therapy; D013997:Time Factors; D014523:Urethral Neoplasms / Q000150:complications* / Q000188:drug therapy
D000700:Analgesics; D007649:Ketamine; D009020:Morphine; D003000:Clonidine